These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10537768)

  • 1. The potential of neuroprotection in glaucoma treatment.
    Osborne NN; Chidlow G; Nash MS; Wood JP
    Curr Opin Ophthalmol; 1999 Apr; 10(2):82-92. PubMed ID: 10537768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned.
    Osborne NN
    Acta Ophthalmol; 2009 Jun; 87(4):450-4. PubMed ID: 19141144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective Strategies in Glaucoma.
    Gossman CA; Christie J; Webster MK; Linn DM; Linn CL
    Curr Pharm Des; 2016; 22(14):2178-92. PubMed ID: 26818878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in glaucoma: recent advances and clinical translation.
    Guymer C; Wood JP; Chidlow G; Casson RJ
    Clin Exp Ophthalmol; 2019 Jan; 47(1):88-105. PubMed ID: 29900639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in relation to retinal ischemia and relevance to glaucoma.
    Osborne NN; Ugarte M; Chao M; Chidlow G; Bae JH; Wood JP; Nash MS
    Surv Ophthalmol; 1999 Jun; 43 Suppl 1():S102-28. PubMed ID: 10416754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria.
    Osborne NN
    Prog Brain Res; 2008; 173():339-52. PubMed ID: 18929120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease progression and the need for neuroprotection in glaucoma management.
    Varma R; Peeples P; Walt JG; Bramley TJ
    Am J Manag Care; 2008 Feb; 14(1 Suppl):S15-9. PubMed ID: 18284311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in glaucoma: recent and future directions.
    Danesh-Meyer HV
    Curr Opin Ophthalmol; 2011 Mar; 22(2):78-86. PubMed ID: 21252670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma.
    Fu QL; Li X; Yip HK; Shao Z; Wu W; Mi S; So KF
    Neuroscience; 2009 Aug; 162(2):375-82. PubMed ID: 19422885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glaucoma: Focus on mitochondria in relation to pathogenesis and neuroprotection.
    Osborne NN; Núñez-Álvarez C; Joglar B; Del Olmo-Aguado S
    Eur J Pharmacol; 2016 Sep; 787():127-33. PubMed ID: 27090928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection: is it already applicable to glaucoma therapy?
    Ritch R
    Curr Opin Ophthalmol; 2000 Apr; 11(2):78-84. PubMed ID: 10848224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection for glaucoma: Requirements for clinical translation.
    Levin LA; Crowe ME; Quigley HA;
    Exp Eye Res; 2017 Apr; 157():34-37. PubMed ID: 27955999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma.
    Osborne NN; Wood JP; Chidlow G
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):175-81. PubMed ID: 15969634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection in glaucoma.
    Tamm ER; Grehn F; Pfeiffer N
    Cell Tissue Res; 2013 Aug; 353(2):201-3. PubMed ID: 23812823
    [No Abstract]   [Full Text] [Related]  

  • 15. Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma.
    Yadav KS; Sharma S; Londhe VY
    Life Sci; 2020 Feb; 243():117303. PubMed ID: 31953158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal ganglion cell neuroprotection induced by activation of alpha7 nicotinic acetylcholine receptors.
    Mata D; Linn DM; Linn CL
    Neuropharmacology; 2015 Dec; 99():337-46. PubMed ID: 26239818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I].
    Rokicki W; Dorecka M; Romaniuk W
    Klin Oczna; 2007; 109(7-9):349-52. PubMed ID: 18260296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma.
    Pirhan D; Yüksel N; Emre E; Cengiz A; Kürşat Yıldız D
    Curr Eye Res; 2016; 41(1):59-69. PubMed ID: 25658983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection in glaucoma--delusion, reality or hope?
    Dimovska-Jordanova A
    Prilozi; 2012; 33(2):163-73. PubMed ID: 23425879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies.
    Osborne NN; Wood JP; Melena J; Chao HM; Nash MS; Bron AJ; Chidlow G
    Eye (Lond); 2000 Jun; 14 ( Pt 3B)():454-63. PubMed ID: 11026974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.